Helper role of NK cells during the induction of anticancer responses by dendritic cells

Pawel Kalinski, Adam Giermasz, Yutaro Nakamura, Per Basse, Walter J. Storkus, John M. Kirkwood, Robbie B. Mailliard

Research output: Contribution to journalReview article

92 Citations (Scopus)

Abstract

Recent reports demonstrate that natural killer (NK) cells and dendritic cells (DC) support each other's activity in a positive feedback. We observed that activated NK cells induce the maturation of DCs into stable type-1 polarized DCs (DC1), characterized by up to 100-fold enhanced ability to produce IL-12p70 in response to subsequent interaction with Th cells. DC1 induction depends on NK cell-produced IFN-γ and TNF-α, with a possible involvement of additional factors. DC1, induced by NK cells or by NK cell-related soluble factors, are stable, resistant to tumor-related suppressive factors, and show strongly enhanced ability to induce Th1 and CTL responses. In analogy to resting T cells, the induction of "helper" function of NK cells relies on a two-signal activation paradigm. While NKG2D-dependent tumor cell recognition is sufficient to induce the cytotoxic "effector" function of NK cells, the induction of "NK cell help" requires additional signals from type-1 IFNs, products of virally-infected cells, or from IL-2. Compared to non-polarized DCs currently-used in clinical trials, DC1s act as superior inducers of anti-cancer CTL responses during in vitro sensitization. The current data provides rationale for the clinical use of DC1s in cancer and chronic infections (such as HIV), as a new generation DC-based vaccines, uniquely combining fully mature DC status with an elevated, rather than "exhausted" ability to produce bioactive IL-12p70. We are currently implementing stage I/II clinical trials, testing the effectiveness of DC1s induced by NK cells or by NK cell-related factors, as therapeutic vaccines against melanoma.

Original languageEnglish (US)
Pages (from-to)535-539
Number of pages5
JournalMolecular Immunology
Volume42
Issue number4 SPEC. ISS.
DOIs
StatePublished - Feb 2005

Fingerprint

Natural Killer Cells
Dendritic Cells
Neoplasms
Vaccines
Clinical Trials
Helper-Inducer T-Lymphocytes
Interleukin-2
Melanoma
HIV
Infection

Keywords

  • Cancer
  • Clinical trials
  • CTL
  • Dendritic cells
  • Immunotherapy
  • NK cells
  • Th1
  • Vaccines

ASJC Scopus subject areas

  • Molecular Biology
  • Immunology

Cite this

Kalinski, P., Giermasz, A., Nakamura, Y., Basse, P., Storkus, W. J., Kirkwood, J. M., & Mailliard, R. B. (2005). Helper role of NK cells during the induction of anticancer responses by dendritic cells. Molecular Immunology, 42(4 SPEC. ISS.), 535-539. https://doi.org/10.1016/j.molimm.2004.07.038

Helper role of NK cells during the induction of anticancer responses by dendritic cells. / Kalinski, Pawel; Giermasz, Adam; Nakamura, Yutaro; Basse, Per; Storkus, Walter J.; Kirkwood, John M.; Mailliard, Robbie B.

In: Molecular Immunology, Vol. 42, No. 4 SPEC. ISS., 02.2005, p. 535-539.

Research output: Contribution to journalReview article

Kalinski, P, Giermasz, A, Nakamura, Y, Basse, P, Storkus, WJ, Kirkwood, JM & Mailliard, RB 2005, 'Helper role of NK cells during the induction of anticancer responses by dendritic cells', Molecular Immunology, vol. 42, no. 4 SPEC. ISS., pp. 535-539. https://doi.org/10.1016/j.molimm.2004.07.038
Kalinski, Pawel ; Giermasz, Adam ; Nakamura, Yutaro ; Basse, Per ; Storkus, Walter J. ; Kirkwood, John M. ; Mailliard, Robbie B. / Helper role of NK cells during the induction of anticancer responses by dendritic cells. In: Molecular Immunology. 2005 ; Vol. 42, No. 4 SPEC. ISS. pp. 535-539.
@article{dcc2b1bd1fcf419182ed01feba497116,
title = "Helper role of NK cells during the induction of anticancer responses by dendritic cells",
abstract = "Recent reports demonstrate that natural killer (NK) cells and dendritic cells (DC) support each other's activity in a positive feedback. We observed that activated NK cells induce the maturation of DCs into stable type-1 polarized DCs (DC1), characterized by up to 100-fold enhanced ability to produce IL-12p70 in response to subsequent interaction with Th cells. DC1 induction depends on NK cell-produced IFN-γ and TNF-α, with a possible involvement of additional factors. DC1, induced by NK cells or by NK cell-related soluble factors, are stable, resistant to tumor-related suppressive factors, and show strongly enhanced ability to induce Th1 and CTL responses. In analogy to resting T cells, the induction of {"}helper{"} function of NK cells relies on a two-signal activation paradigm. While NKG2D-dependent tumor cell recognition is sufficient to induce the cytotoxic {"}effector{"} function of NK cells, the induction of {"}NK cell help{"} requires additional signals from type-1 IFNs, products of virally-infected cells, or from IL-2. Compared to non-polarized DCs currently-used in clinical trials, DC1s act as superior inducers of anti-cancer CTL responses during in vitro sensitization. The current data provides rationale for the clinical use of DC1s in cancer and chronic infections (such as HIV), as a new generation DC-based vaccines, uniquely combining fully mature DC status with an elevated, rather than {"}exhausted{"} ability to produce bioactive IL-12p70. We are currently implementing stage I/II clinical trials, testing the effectiveness of DC1s induced by NK cells or by NK cell-related factors, as therapeutic vaccines against melanoma.",
keywords = "Cancer, Clinical trials, CTL, Dendritic cells, Immunotherapy, NK cells, Th1, Vaccines",
author = "Pawel Kalinski and Adam Giermasz and Yutaro Nakamura and Per Basse and Storkus, {Walter J.} and Kirkwood, {John M.} and Mailliard, {Robbie B.}",
year = "2005",
month = "2",
doi = "10.1016/j.molimm.2004.07.038",
language = "English (US)",
volume = "42",
pages = "535--539",
journal = "Molecular Immunology",
issn = "0161-5890",
publisher = "Elsevier Limited",
number = "4 SPEC. ISS.",

}

TY - JOUR

T1 - Helper role of NK cells during the induction of anticancer responses by dendritic cells

AU - Kalinski, Pawel

AU - Giermasz, Adam

AU - Nakamura, Yutaro

AU - Basse, Per

AU - Storkus, Walter J.

AU - Kirkwood, John M.

AU - Mailliard, Robbie B.

PY - 2005/2

Y1 - 2005/2

N2 - Recent reports demonstrate that natural killer (NK) cells and dendritic cells (DC) support each other's activity in a positive feedback. We observed that activated NK cells induce the maturation of DCs into stable type-1 polarized DCs (DC1), characterized by up to 100-fold enhanced ability to produce IL-12p70 in response to subsequent interaction with Th cells. DC1 induction depends on NK cell-produced IFN-γ and TNF-α, with a possible involvement of additional factors. DC1, induced by NK cells or by NK cell-related soluble factors, are stable, resistant to tumor-related suppressive factors, and show strongly enhanced ability to induce Th1 and CTL responses. In analogy to resting T cells, the induction of "helper" function of NK cells relies on a two-signal activation paradigm. While NKG2D-dependent tumor cell recognition is sufficient to induce the cytotoxic "effector" function of NK cells, the induction of "NK cell help" requires additional signals from type-1 IFNs, products of virally-infected cells, or from IL-2. Compared to non-polarized DCs currently-used in clinical trials, DC1s act as superior inducers of anti-cancer CTL responses during in vitro sensitization. The current data provides rationale for the clinical use of DC1s in cancer and chronic infections (such as HIV), as a new generation DC-based vaccines, uniquely combining fully mature DC status with an elevated, rather than "exhausted" ability to produce bioactive IL-12p70. We are currently implementing stage I/II clinical trials, testing the effectiveness of DC1s induced by NK cells or by NK cell-related factors, as therapeutic vaccines against melanoma.

AB - Recent reports demonstrate that natural killer (NK) cells and dendritic cells (DC) support each other's activity in a positive feedback. We observed that activated NK cells induce the maturation of DCs into stable type-1 polarized DCs (DC1), characterized by up to 100-fold enhanced ability to produce IL-12p70 in response to subsequent interaction with Th cells. DC1 induction depends on NK cell-produced IFN-γ and TNF-α, with a possible involvement of additional factors. DC1, induced by NK cells or by NK cell-related soluble factors, are stable, resistant to tumor-related suppressive factors, and show strongly enhanced ability to induce Th1 and CTL responses. In analogy to resting T cells, the induction of "helper" function of NK cells relies on a two-signal activation paradigm. While NKG2D-dependent tumor cell recognition is sufficient to induce the cytotoxic "effector" function of NK cells, the induction of "NK cell help" requires additional signals from type-1 IFNs, products of virally-infected cells, or from IL-2. Compared to non-polarized DCs currently-used in clinical trials, DC1s act as superior inducers of anti-cancer CTL responses during in vitro sensitization. The current data provides rationale for the clinical use of DC1s in cancer and chronic infections (such as HIV), as a new generation DC-based vaccines, uniquely combining fully mature DC status with an elevated, rather than "exhausted" ability to produce bioactive IL-12p70. We are currently implementing stage I/II clinical trials, testing the effectiveness of DC1s induced by NK cells or by NK cell-related factors, as therapeutic vaccines against melanoma.

KW - Cancer

KW - Clinical trials

KW - CTL

KW - Dendritic cells

KW - Immunotherapy

KW - NK cells

KW - Th1

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=10644249213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10644249213&partnerID=8YFLogxK

U2 - 10.1016/j.molimm.2004.07.038

DO - 10.1016/j.molimm.2004.07.038

M3 - Review article

VL - 42

SP - 535

EP - 539

JO - Molecular Immunology

JF - Molecular Immunology

SN - 0161-5890

IS - 4 SPEC. ISS.

ER -